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Nanomaterials-based phototherapies, mainly including photothermal therapy (PTT),
photodynamic therapy (PDT) and photoimmunotherapy (PIT), present high efficacy,
minimal invasion and negligible adverse effects in cancer treatment. The integrated
phototherapeutic modalities can enhance the efficiency of cancer immunotherapy
for clinical application transformation. The near-infrared (NIR) light source enables
phototherapies with the high penetration depth in the biological tissues, less toxic to
normal cells and tissues and a low dose of light irradiation. Mediated via the novel NIR-
responsive nanomaterials, PTT and PDT are able to provoke cancer cells apoptosis
from the generated heat and reactive oxygen species, respectively. The released cancer-
specific antigens and membrane damage danger signals from the damaged cancer cells
trigger immune responses, which would enhance the antitumor efficacy via a variety of
immunotherapy. This review summarized the recent advances in NIR-triggered photo-
/immune-therapeutic modalities and their synergistic mechanisms and applications
toward cancers. Furthermore, the challenges, potential solutions and future directions
of NIR-triggered photo-/immunotherapy were briefly discussed.
Keywords: cancer phototherapy, near infrared light, photo/immune-therapy, photothermal therapy (PTT),
photodynamic therapy, cancer
INTRODUCTION
Cancer is still one of the top leading causes of mortality after many decades’ search and exploration
for a cure in cancer from diagnosis and therapy. Currently, the available treatments to cancers
in clinics are mainly surgery, chemotherapy and radiotherapy. A number of newly developed
therapeutic modalities have been selectively adopted or in preliminary clinical trials including
gene therapy, targeted therapy, immunotherapy, phototherapy (photothermal and photodynamic),
magnetic hyperthermia therapy and other non-mainstream treatments.
The tumor cell death are caused in virtue of extrinsic stimuli in most of the aforementioned
therapeutic modalities, such as chemotherapy mediated by chemotherapeutic agents, radiotherapy
via various energy rays, hyperthermia therapy from the external high-frequency magnetic field,
and phototherapy attributed to external light energy sources. Photothermal therapy (PTT) and
photodynamic therapy (PDT) are the two representative phototherapy and are used for the tumor
cells destruction through heat or reactive oxygen species respectively under irradiation of light.
The external stimuli therapeutic approaches show significant advance in ablating solid primary
tumors. However, the side effects from the extrinsic stimuli are quite strong and the recurrence of
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cancers is not controllable. Among the extrinsic stimuli, light
energy in phototherapy offers lowest side effects and least
systemic toxicity. Near-infrared (NIR) light is the preferable light
source due to its superior tissue penetration ability. Under light
irradiation, phototherapeutic agents that are little toxic in dark
are turned into functional ones to selectively destroy cancer cells,
without causing much damage to surrounding healthy tissues
(Cheng et al., 2014).
While gene therapy and immunotherapy toward cancers
are fulfilled owing to the intrinsic biological response of
genes and immune systems to fight against cancers. Cancer
immunotherapy approach, utilizing the patient’s own immune
system to trigger or enhance the antitumor response (Galluzzi
et al., 2018; Sahin and Türeci, 2018), offers several advantages
over the extrinsic therapeutic methods, such as low side
effects, effective treatment of metastatic cancers, and generation
of immunological memory to prevent recurrence (Jo et al.,
2017). The five typical types of immunotherapies to treat
cancer is summarized in Figure 1 (Sang et al., 2019).
Systemic administration of cytokines is the first developed
immunotherapy approach. Cytokines, such as interleukins
(ILs) and interferon (INF), have shown significant antitumor
activity via their immune regulation effects (Smyth et al.,
2004). Therapeutic cancer vaccines are developed for active
immunotherapies to treat late-stage cancers by harnessing the
patient’s own immune system, including peptide vaccines, whole
tumor cell vaccines, dendritic cell (DC) vaccines and genetic
vaccines (Guo et al., 2013). As the first Food and Drug
Administration (FDA) approved therapeutic cancer vaccine,
the DC-based vaccine sipuleucel-T (Provenge R©) has been
used to treat prostate cancer since 2010 (Plosker, 2011),
which may drive possible success for therapeutic vaccination
strategies (Hollingsworth and Jansen, 2019; Mougel et al.,
2019). Adoptive T cell transfer therapy (Kalos and Carl June,
2013) is an approach that T cells with specific chimeric
antigen receptors are returned back to patient’s body to
eliminate cancer cells specifically after isolation, stimulation
and reinfusion of tumor-infiltrating lymphocytes with potent
antitumor activity. Recently, immune checkpoint pathways
have entered the limelight in cancer immunotherapy because
these immune checkpoint pathways control the amplitude and
duration of immune responses to many cancers (Pardoll, 2012).
Monoclonal antibodies, such as Ipilimumab targeting cytotoxic
T lymphocyte-associated antigen 4 (CTLA-4) (Hodi et al., 2010),
Atezolizumab targeting programmed death 1 (PD-1) receptor
(Krishnamurthy and Jimeno, 2017), have been approved by FDA
as immune checkpoint blocker for the treatments of metastatic
melanoma and metastatic urothelial carcinoma or non-small-
cell lung cancer, respectively. However, the immunomodulatory
monoclonal antibodies have demonstrated severe immune-
related adverse effects on healthy cells (Postow et al., 2015).
To achieve the ultimate goal of eradicating primary tumors
and metastasizes simultaneously, utilization of synergistic
therapeutic modalities with extrinsic and intrinsic mechanisms
for outstanding super-additive therapeutic effects to cancers is
demanding and promising in current researches (Sang et al.,
2019). Extrinsic stimuli can induce immunogenic cell death
(ICD) (Kroemer et al., 2013; Panzarini et al., 2013) which would
release damaged-associated molecular patterns (DAMPs) thereby
increase the immunogenicity of the tumor microenvironment
from chemotherapy (Dudek et al., 2013), radiotherapy (Weiss
et al., 2016), and phototherapy (Mroz et al., 2011). However,
the resulting immune signals from the extrinsic stimuli are
not sufficient and efficient to trigger the immune system for
tumor erosion (Sang et al., 2019). Therefore, combining these
cancer therapies with emerging immunotherapy is intuitive
to overcome the limitations and maximize the merits of
therapeutic modalities. From the point of view of low side effects,
photoimmunotherapy (PIT), which is a synergistic therapy
modality combining of phototherapy and immunotherapy
toward cancers, demonstrates great potential benefits. While
for the therapeutic window consideration, synergistic cancer
therapy integrating phototherapy and immunotherapy would
be the optimal. An optimal therapeutic window, quantified by
therapeutic index, is critical to provide meaningful improvements
in survival. Efforts should be aimed at increasing the therapeutic
index, resulting in augmented efficacy in the elimination of
primary tumor, metastasis of distant tumor and prevention
of recurrence from long-term immune memory function.
For the specific therapy modality, the therapeutic window
can be improved from different aspects. For examples, the
therapeutic index of PDT could be increased by extending
the light delivery intervals (Ris et al., 1993). Exploitation of
photosensitizers with low dark toxicities and high extinction
coefficients may also allow the administration of higher
doses of phototherapy agents and NIR light, resulting in
higher therapeutic index (Boyle et al., 1992). An example is
the use of Diiodo-substituted BODIPYs as a non-porphyrin
photosensitizer for PDT improved the killing efficiency of
melanoma B16F10 cells (Wang W. et al., 2016). Wei et al.
(2019) reported a type of PIT agent, IR700-YY146, achieved
high therapeutic index for melanomas of relatively smaller
volumes. However, the treatment efficacy for larger tumors
was not ideal due to the penetration of light through skin
and tissues into the large tumor. Repeated treatment and
increased the energy transfer ratio of the PIT agents may be
helpful to treat large and deep tumors (Mallidi et al., 2016;
Wei et al., 2019).
In this review, researches on NIR light-triggered
photoimmunotherapy in last decade (2010∼2019) toward
cancers using nanomaterials are collected and discussed. We first
describe the therapeutic effects on cancers using the synergistic
PIT of immunotherapy with PDT and PTT followed with
photochemistry-based cancer therapy. Lastly, a conclusion and
future perspective are drawn at the end.
PHOTOIMMUNOTHERAPY
Phototherapy is a non-invasive or minimally invasive therapeutic
strategy. In cancer treatment, phototherapy not only kill tumor
cells directly but also induces ICD to initiate a systemic antitumor
immune response, including the redistribution and activation of
immune effector cells, the expression and secretion of cytokines
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FIGURE 1 | An illustrated summary of the significant cancer immunotherapeutic approaches (Sang et al., 2019). The immunotherapies function through five key
components (a) Cytokines, (b) Therapeutic vaccines, (c) Adoptive cell transfer. (d) Checkpoint blockade. (e) Binding between antibodies and tumor antigens.
Reproduced with permission from reference Sang et al. (2019).
and the transformation of memory T lymphocytes (Hou et al.,
2018; Li et al., 2019b).
Combining phototherapy and immunotherapy for cancer
treatment, the merits of the two will be augmented while
inherent shortfalls are minimized. The general principles that
allow phototherapy to greatly enhance the immunotherapy
effects have been summarized by Pu’s group in a review
(Ng et al., 2018) and the working mechanisms are shown in
Figure 2. Firstly, phototherapy should be capable of effective
eradication of primary tumors; Subsequently, the released
tumor-specific antigens would serve as the substrates for an
in situ autovaccine (Chen et al., 2016); Similarly, ICD during
phototherapy would release DAMPs which are capable of
triggering immune responses and thus strengthen the inherently
weak immunostimulatory properties of native tumor antigens
(Mroz et al., 2011); Lastly, the pro-inflammatory cytokines
designed to activate the immune system are also elevated. On
the other hand, immunotherapy then plays its part at the
meantime with phototherapy via (1) increasing immunogenicity
of the tumor microenvironment (utilizing immunoadjuvants),
eventually attracting more antigen-presenting dendritic cells
or (2) decreasing immunoregulatory suppression (immune
checkpoint blockade therapy). In the last, the combined
two therapeutic modalities could effectively eliminates the
primary tumor, clears up residual tumor cells and tracks
metastatic tumor sites. Phototherapy mainly is based on
nanomaterials and nanotechnologies for their specific and
selective effects on targeted disease lesion. Phototherapeutic
modalities include PDT, PTT and photochemistry-based therapy,
have attracted tremendous interest in both research and clinic
aspects. The synergistic effects of each these phototherapeutic




PTT is one of the hyperthermia treatment to cancers through
the administrated photoactive agents (Photosensitizers) that
convert photon energy into thermal energy (Nam et al.,
2019). Tumor cells can be killed at a temperature of 40–44◦C
with the invasive light irradiation, which would cause DNA
damage, protein denaturation and plasma membrane disruption
(Hildebrandt et al., 2002). In addition, the febrile temperature
can trigger immune responses through the transcription of
heat shock proteins and increased recruitment of lymphocytes
to tissues with elevated temperature (Evans et al., 2015). The
PTT induced tumor ablation can also induce the release of
tumor antigens and immune-stimulatory molecules, thereby
further activating the innate immunity and the adaptive
immune system to kill residual or metastatic tumors (Hou
et al., 2018). The photothermal-mediated immune response
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FIGURE 2 | An overview of the working mechanism for the combined phototherapy and immunotherapy for cancer treatment (Ng et al., 2018). Reproduced with
permission from reference Ng et al. (2018).
within the nanoparticles-based PTT has been illustrated in
details by Rajendrakumar et al. (2018) and is shown in
Figure 3.
NIR light has been widely used as the light source for
PTT exhibiting minimal absorption and scattering by tissue
components, thus NIR is able to achieve deep tissue penetration.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 4 May 2020 | Volume 8 | Article 488
fbioe-08-00488 May 22, 2020 Time: 19:44 # 5
Xu et al. NIR Light Triggered Photo/Immuno-Therapy
FIGURE 3 | The processes of immunotherapy mediated by nanoparticle-based PTT (A) and the tumor recurrence. There are eight steps to treat tumors after the
PTT under NIR irradiation: (1) The ablated tumor cells release antitumor antigens (2) and proinflammatory cytokines. Then (3) the cytokines and antigens promote the
maturation of dendritic cells in the tumor-draining lymph node (4) and help to recruit myeloid-derived suppressor cells (MDSCs) and CD8+ and CD4+ T cells. (5) The
CD8+ T cells can induce an antitumor immune response. In the tumor recurrence, (6) the MDSC infiltrate in the tumor, (7) and release anti-inflammatory cytokines, (8)
CD4 + FOXP3 + Treg cells are activated by MDSCs and inhibit the antitumor immune response, (9) the maturation of dendritic cells is blocked by anti-inflammatory
cytokines and activated Treg cells, and (10) the overall action of MDSCs causes tumor remission (Rajendrakumar et al., 2018). Reproduced with permission from
reference Rajendrakumar et al. (2018).
Bear et al. (2013) demonstrated an effective tumor ablation
strategy which adopted optically tunable gold hollow nanoshells
to generate heat upon exposure to NIR radiation (808 nm). The
PTT subsequently promoted the expression of pro-inflammatory
cytokines (IL-6, IL-1β, IL-I2p70) and chemokines (CXCL1,
CCL2, and CCL4) and induced maturation of dendritic cells
within tumor-drain lymph nodes. Wang et al. (2014) also
reported the photothermal ablation of primary tumors using
single-walled carbon nanotubes (SWCNTs) that were able to
strongly absorb NIR light of 808 nm and resulted in the release
of tumor-associated antigens. However, the single model of NIR-
PTT induced immune response is insufficient to control the
growth of the distal tumor or metastases owing to suboptimal
activation. PTT promotes the generation of immunosuppressive
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myeloid-derived suppressor cells (Bear et al., 2013) and induces
the temperature-dependent adverse effects on cytokines and
chemokines (Nam et al., 2019).
The more effective way is to integrate the two therapeutic
modalities, PTT and immunotherapy, together to target the
primary tumor ablation as well as the metastatic cancer
cell growth. The typical immunotherapy methods have been
combined with PTT via either separate but subsequent
administration or single and simultaneous administration. For
example, the elimination of metastatic melanoma was achieved
using gold nanoshell-enabled PTT together with adoptive T
cell transfer immunotherapy 24 h following PTT (Bear et al.,
2013). While a cytotoxic T lymphocyte antigen-4 (CTLA-4)
blockade strategy was applied into mice with breast cancer or
lung cancer after the tumor ablation by PTT, the antitumor
efficacy was much promoted leading to effective rejection of
secondary tumors and minimized tumor metastasis (Wang
et al., 2014). An interventional PTT using an optical fiber
with a NIR light of 980 nm was inserted into tumor center
and an immunoadjuvant agent of glycated chitosan (GC) was
intratumor-injected immediately after PTT in mouse pancreatic
tumor model. The complete regression was achieved and more
importantly, it triggered tumor-specific immune memory and
the production of memory T cells to inhibit tumor rechallenge
(Zhou et al., 2018). Ma et al. (2019) adopted a second NIR
(NIR II at 1086 nm) light to carry out the PTT. Compared
to the red light (680 nm) and NIR I light (808 nm), NIR II
light-triggered more homogeneous release and distribution of
DAMPs from ICD in the deeper part of solid tumors via a
gold photothermal transducer. The NIR II PTT combining with
checkpoint blockade therapy enabled long-term tumor control
over both primary and secondary tumors. Another NIR II
transducer, polypyrrole nanosheets, showed striking therapeutic
effects against whole-body tumor metastasis via the synergistic
photothermal-immunological response.
Guo et al. (2014) integrated the immunoadjuvant
oligodeoxynucleotides containing cytosine-guanine (CpG)
motifs onto the NIR light-responsive photosensitizer, chitosan-
coated hollow CuS nanoparticles, and applied in a single dosage
into a mouse breast cancer model. In this work, a pulsed NIR
laser at 900 nm was employed. The hollow CuS absorbed the
NIR light and conducted the PTT ablation to primary tumor.
Upon the energy conversion, hollow CuS degraded into small
nanoparticles and coated chitosan and the CpG assembled into
chitosan-CpG nanocomplexes that potentiated host antitumor
immunity against distant untreated tumors. The working
mechanism is shown in Figure 4.
An immunoadjuvant agent, resiquimod R848, was loaded
into the polydopamine nanoparticles as photothermal conversion
agent together with carbon dots as imaging agent. Under 808 nm
NIR light irradiation, the polydopamine can utilize hyperthermia
to perform PTT to eliminate the primary 4T1 breast tumor
cells. After the PTT, the generated and released tumor–associated
antigens along with the PTT could be amplified by R848
and further triggered stronger infiltration of CTLs into distant
tumors. In addition, The long-term immune memory effect was
induced to prevent tumor reoccurrence (Lu et al., 2019).
FIGURE 4 | A schematic of the immunotherapy to both primary treated and
distant untreated tumors mediated by chitosan-coated hollow CuS
nanoparticles loaded with CpG (HCuSNPs-CpG). Upon the irradiation of
900 nm NIR light, the intratumorally injected HCuSNPs-CpG transformed to
chitosan-CpG nanocomplexes (Chi-CpG-NPs) that can be internalize into
Toll-like receptor 9-rich endosomes of plasmacytoid dendritic cells (pDCs).
These dendritic cells produce interferon-R (IFN-R) by the stimulation with
CpG, which can promote innate immunity through neutral killer (NK) cell
activation. Meanwhile, the photothermal ablation by irradiated CuP
nanoparticles destroys the tumor cells and releases tumor-associated
antigens to attract and activate myeloid dendritic cells (mDCs). These mDCs
become antigen-presenting cells with the help of IFN-R secreted by the pDCs.
The antigen-presenting mDCs then migrate to tumor-draining lymph nodes
(DLNs) and activate tumor antigen-specific T cells. These CD8+ T cells enter
the systemic circulation and migrate to both primary tumor and distant tumor
sites to provoke the “effector phase” of the adaptive immune response (Guo
et al., 2014). Reproduced with permission from reference Rajendrakumar
et al. (2018).
Two different immunotherapy methods can be synergized
with PTT to effectively suppress primary tumors and to
inhibit metastasis. Li et al. (2019a) investigated the use of
the immunoadjuvant agent, glycated Chitosan (GC), modified
SWCNTs with NIR laser irradiation to potentiate anti-CTLA
checkpoint blockade therapy in a highly aggressive 4T1 murine
breast cancer model. The SWCNTs was adopted to achieve
selective ablation of primary tumor by locally absorbing a
1064 nm NIR light and the release of tumor antigens in the
tumor microenvironment, while the GC further stimulated the
host immune cells and induced antitumor immune response. The
combined use of anti-CTLA checkpoint blockade to suppress
the activity of immunosuppressive regulatory T cells induced a
systemic antitumor immunity which inhibited lung metastasis
and prolonged the animal survival time.
Although the PTT induced immunotherapy efficacy is low
and weak, the combined PTT with different immunotherapy
has achieved substantial immune stimulation and overcome
immunosuppression within the tumor microenvironment. More
efforts are still required to explore synergistic and efficient PTT
and immunotherapy.
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Photodynamic Therapy Synergized
Immunotherapy
PDT has been approved by the FDA for advanced cancer
patients and it has been applied in clinic for various diseases
with unique advantages in minimal invasiveness, low toxic
side effects, good selectivity, and reproductivity (Park et al.,
2018). In PDT, a photosensitizer (PS) is essentially employed to
absorb the specific light energy for the generation of cytotoxic
reactive oxygen species (ROS), such as singlet oxygen, H2O2
and hydroxyl and superoxide anion radicals (Chatterjee et al.,
2008; Qiu et al., 2018). The ROS damages subcellular organelles
and plasma membranes, thereby induce oxidative-stress-based
cell death and destroy the functions of vascular surrounding
the tumors. The dying tumor cells release tumor antigens and
cytosolic components that provoke inflammation and stimulate
immune systems. The illustration for PDT-mediated immune
response following tumor necrosis after PDT is shown in Figure 5
(Rajendrakumar et al., 2018).
Similar to the PTT, PDT alone induces the relatively weak
and insufficient immune response to inhibit distant metastasis
while combined PDT and immunotherapy demonstrate great
potential for both the primary tumor ablation and metastatic
cancer cells inhibition (Wang D. et al., 2016). Compared to
the hydrophobic organic photosensitizers which can selectively
target in specific intracellular organelles, such as tetrapyrrole and
phenothiazinium, the inorganic photosensitizers show improved
PDT performances in targeted delivery and accumulation
in tumor tissues and specific subcellular compartments and
also in increased colloidal stability and photoresponsiveness
(Abrahamse and Michael Hamblin, 2016). Single PDT using
gold nanocages@MnO2 nanostructures as the photosensitizer
was employed for enhanced PDT effect and boosted antitumor
immune responses against metastatic triple-negative breast
cancer. The primary problem targeted in this work was the
local hypoxia tumor environment which not only severely
decreased the PDT efficacy, but also caused immunosuppression
by inhibiting T cells from entering tumor environment.
The MnO2 shell degraded in the acidic (pH 6.5) tumor
microenvironment and generated massive oxygen which was
utilized for the production of powerful ROS from the gold
nanocages under the irradiation of NIR 808 nm. The primary
tumor could be destroyed by these ROS, at the same time,
the immunogenic cell death–mediated antitumor immune
response from DAMPs was elicited to inhibitate lung metastasis
(Liang et al., 2018).
Upconversion nanoparticles (UCNPs) is an emerging
luminescent nanomaterials with potential advantageous
benefits for PDT. UCNPs are able to transfer the NIR light
energy (commonly 980 or 808 nm NIR lights) into required
high energy light (visible and ultraviolet lights) to excite
the combined photosensitizers for the ROS generation. Xu
et al. (2017) designed and constructed a multitasking UCNPs
nanocomplex with a photosensitizer (Ce6) and a Toll-like-
receptor-7 agonist (R837). The UCNP-Ce6-R837 nanocomplex
was injected intratumorally into the tumor. Under 980 nm
NIR light irradiation, the effective PDT destruction of the
tumor can generate a pool of tumor-associated antigens,
which was powered by the adjuvant of R837 to stimulate
strong antitumor immune responses. Further combined
with the checkpoint blockade immunotherapy method with
CTLA-4, it has been achieved for the excellent efficacy in
eliminating tumors exposed to the NIR laser and also in
inhibiting the growth of distant tumors through stimulated
antitumor immunities as well as long term immune memory
function from reoccurrence of colorectal cancer. The working
mechanism is shown in Figure 6. Lin’s group (Ding et al., 2018)
designed large pore silica coated UCNPs based nanovaccine
system in which photosensitizer, model protein (chicken
ovalbumin, OVA) for T cell and cytokine evoke measurement
and therapeutic vaccine to tumor (tumor cell fragment)
could be loaded with much high loading efficiency (30 and
33.5% respectively). Both the great cellular uptake and the
largely loading capacities of the prepared UCNPs–MC540
enabled much improved PDT efficacy, enhanced synergistic
immunopotentiation actions to T cells and cytokines, and
significant in vivo antitumor-therapy efficacy under 980 nm
NIR irradiation.
The limitations for the PDT exist in the biosafety concern
of photosensitizers, the penetration depth of the light source
(NIR light can penetrate around 1 cm penetration in tissues),
and less efficacy to large solid tumors. In spite of these
limitations, PDT combining with immunotherapy is still a
promising approach for advanced cancer treatment (Sang
et al., 2019). A great deal of efforts has been contributed
to develop biocompatible photosensitizers and optimize the




Other than the two typical phototherapy modality, PTT and
PDT, NIR light is also adopted to trigger antitumor immunity
as photo-immunotherapy toward cancers. NIR light was used
to initiate photochemistry reactions of the photosensitizer and
thus induce the immunotherapy. Kobayashi’s group (Kobayashi
and Choyke, 2019) proposed a new molecularly targeted
cancer photo-therapy, NIR-PIT, which is based on a NIR
silica-phthalocyanine dye, IR Dye 700DX (IR700), conjugated
to cell-surface molecules targeting monoclonal antibody
(mAb) (Ogata et al., 2017). The water-soluble conjugated
mAb with IR700 was injected into the body and the mAb
targeted an expressed antigen on cancer cell surfaces. The
working mechanism of the NIR-PIT is presented in Figure 7
(Sato et al., 2018). Subsequent local exposure to NIR light
would photodegrade the IR700 molecules by releasing the
hydrophilic side chains, which converted the IR700 molecules
on the cancer cell surfaces into hydrophobic. This conversion
from hydrophilicity to hydrophobicity quenched the IR700
fluorescence due to the formation of a Z-stack multimer
of silicon-phthalocyanine IR700 rings or water-insoluble
aggregates of antibody-photo absorber conjugate (APC) or
APC-antigen complexes. The cell membrane integrity would
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FIGURE 5 | The process of the photodynamic-mediated cancer immunotherapy by nanoparticle-based PDT. (A) PDT laser irradiation in photosensitizer
accumulated tumor leads to (1) ROS mediated cell death, (B) after ROS mediated cell death, (2) apoptotic or necrotic cells attracts scavenging cells like mast cells,
neutrophils, and monocytes, (3) apoptotic cancer cells release factors like IL-10, TGF-β, sphingosine-1-phosphate (S1P), monocyte chemoattractant protein-1
(MCP-1) and bombesin (BN), (4) released factors attract monocytes and convert them into M2 macrophages or tumor-associated macrophages (TAMs), and
(C) TAMs accumulated in the tumor site, (6) releases immune-suppressive proteins and cytokines to support the growth and invasion of the tumor (Xu et al., 2017).
Reproduced with permission from reference Rajendrakumar et al. (2018).
be disrupted from the damaging of transmembrane target
proteins via the physicochemical changes to the APC-antigen
complex (Sato et al., 2018; Kobayashi and Choyke, 2019).
Rapid swelling caused large tears in the membrane allowing
the release of intracytoplasmic contents into the extracellular
space (Ogawa et al., 2017). Therefore, the NIR (690 nm)
was used to turn on this photochemical “death” switch to
ablate the primary tumor and to induce the rapid and highly
selective ICD as early as 1 min’s NIR light exposure. NIR-
PIT has been demonstrated to be effective with a variety of
different APCs, including anti-CD20 (Nagaya et al., 2016a)
for B-cell lymphoma, prostate-specific membrane antigen
(PSMA) antibody (Nagaya et al., 2017), antimesothelin
antibody (Hanaoka et al., 2015) and glypican-3 targeted
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FIGURE 6 | A schematic describing the mechanisms of combining NIR-mediated PDT with CTLA-4 checkpoint blockade for cancer immunotherapy. NIR irradiation
to UCNP-Ce6-R837 destroys tumor cells and generate tumor-associated antigens. The R837 acts as the adjuvant to stimulate antitumor immune response.
Incorporation with the CTLA-4, UCNP-Ce6-R837 can inhibit both primary and distant tumors as well as preserve a long-term immune memory to prevent tumor
relapse (Xu et al., 2017). Reproduced with permission from reference Xu et al. (2017).
human heavy chain antibody for hepatocellular cancer
(Nagaya et al., 2016b).
NIR-PIT was also combined with an immunotherapeutic
method of checkpoint blockade (Nagaya et al., 2019). NIR-
PIT monotherapy inhibited tumor growth, promoted tumor
infiltration of dendritic cells, and induced de novo tumor antigen-
specific T-cell responses absent at baseline. The addition of PD-1
blockade reversed adaptive immune resistance, resulting in both
enhanced pre-existing tumor antigen-specific T-cell responses
and enhanced de novo T-cell responses induced by NIR-PIT.
Chu et al. (2019) reported an activatable engineered
immunodevice that enabled remotely control over the antitumor
immunity in vivo with NIR light mediated using upconversion
nanoparticles (UCNPs). It was a smart system with superior
spatiotemporal precision and enhanced safety. The working
mechanism scheme is displayed in Figure 8 (Chu et al., 2019).
The immunodevice was composed of an immunotherapeutic
agent, CpG oligonucleotides (ODNs), a complementary ssDNA
(PcDNA) containing photocleavable bonds to yield PCpG, and
UCNPs. The CpG was hybridized with the PcDNA firstly forming
PCpG which then was integrated onto the UCNPs via cationic
polymers. The constructed PCpG/UCNPs immunodevice could
facilitate the delivery of PCpG into cells. After the cell uptake of
the PCpG/UCNPs, upon the irradiation of NIR light (980 nm),
the UCNPs converted the NIR to UV light to break the
bond of the PcDNA and CpG and released the CpG inside
of the cells. Thereafter, the CpG agent started to play its role
for the immunotherapy to 4T1 tumor with remotely spatially
selective control. This non-invasive strategy presented high
spatiotemporal precision and amenable personalizing antitumor
function with reduced systemic toxicity.
The photochemistry based immunotherapy shows as
high potential as the PTT and PDT with less complexity
in nanomaterials design and working processes. More
advanced photochemistry-based immunotherapy modality
should be working on.
Multiple Phototherapy Synergized
Immunotherapy
The implantation of multi-synergistic therapy relies on the
combination of multiple treatments into a single nanoplatform.
There are more than two phototherapeutic modalities have been
integrated with immunotherapy.
Synergistic therapy integrating multiple NIR photoactivatable
immunotherapeutic strategy has been comprehensively
investigated. Li et al. (2019) developed an organic
semiconducting pro-nanostimulants (OSPS) platform
for synergetic cancer therapy. The OSPS comprised a
semiconducting polymer nanoparticle (SPN) core and an
immune checkpoint inhibitor (NLG919) which was conjugated
together by a singlet oxygen (1O2) cleavable linker. Upon NIR
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FIGURE 7 | A schematic for the chemical reaction of NIR-PIT (top) and the mechanisms underlying the disruption of tumor cells (Liang et al., 2018). Reproduced
with permission from reference Liang et al. (2018).
laser irradiation, the SPN core within OSPS could generate
both heat and 1O2 for combinational PTT and PDT of tumors,
leading to the release of tumor-associated antigens. Meanwhile,
the generated 1O2 specifically cleaves the 1O2-cleavable liner to
trigger the on-demand release and simultaneous activation of
caged NLG919, which resulted in the promoted proliferation
and activation of effector T cell but suppression of Treg cells.
Therefore, the synergistic phototherapy with remote-controlled
immune checkpoint blockade therapy exerted an amplified
therapeutic efficacy in inhibition of primary and distant tumor
growth and lung metastasis (Li et al., 2019b) and the working
mechanism is shown in Figure 9.
Targeting for the rational design of smart nanomaterial
that could combine multimodal therapy and overcome their
own inherent limitations, Chen et al. (2019) developed a
multifunctional nanoplatform for synergistic phototherapy
(PDT and PTT), and chemotherapy drug docetaxel (DTX)
enhanced cytokine immunotherapy. Mesoporous CuS
nanoparticles were adopted as the carrier for loading
and delivering chemotherapy drug docetaxel (DTX) and
PTT agent under 808 nm light irradiation. Folic acid
molecules were modified onto the CuS for targeted delivery
and accumulation to tumor site. The photosensitizer,
polyethylenimine-protoporphyrin IX (PEI-PpIX), were then
coated outside of the CuS nanoparticle and the CpG was
further modified onto the CuS surface. The combination
of the four therapeutic modalities in this nanocomplex was
denoted as FA-CD@PP-CpG. Although the FA-CD@PP-CpG
presented remarkably inhabitation to tumor growth without
apparent side effects within a 4T1-tumor-bearing mouse model,
it also showed the complicated conduction for individual
therapies, such as the PDT and PTT under 650 nm 808 nm
light irradiation respectively, chemotherapeutic drug and
immunoadjuvent agent separately release. The synergistic effect
could be improved.
Yan et al. (2019) composed a relatively simple hybrid
nanosystem using polydopamine as core, UCNPs nanoparticles
as the shell and the photosensitizer chlorin e6 (Ce6) as
surface coating. Polydopamine could absorb the excitation
980 nm NIR light and also the emissions of visible light
from UCNPs for PTT. The visible light emission from
UCNPs under NIR excitation was able to excite the Ce6
for PDT. The specific core-shell nanostructure design allowed
adequate photoabsorption for the heat conversion and ROS
generation with NIR light irradiation. Incorporating with
immune checkpoint blocked-based therapy, this nanosystem
inhibited tumor recurrence and metastasis and extended the
survival periods of tumor-bearing mice in metastatic mouse
models (Yan et al., 2019). However, the relatively large size
of the core-shell nanostructure might not be able to have
high accumulative amount in tumor site when systematically
administrated in living mice model.
To increase the immune response induced by phototherapy,
an NIR-triggered antigen-capturing nanoplatform was designed
and fabricated, using UCNPs as carrier, indocyanine green
(ICG) as a light absorber, rose bengal (RB) as photosensitizer
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FIGURE 8 | The mechanism for the antitumor effects of the photoactivatable immunodevice, PCpG/UCs (A) and the in vivo activities for PCpG/UCs (B). PCpG/UCs
can selectively trigger the immunoactivity through NIR light irradiation. In contrast to traditional CpG delivery system (CpG/UCs), PCpG/UCs showed reduced
systemic toxicity (Chu et al., 2019). Reproduced with permission from reference Chu et al. (2019).
and the lipid molecule (DSPE-PEG-maleimide) as the
antigen-capturing agent. The ICG significantly enhanced
the RB-based PDT efficiency of UCNP/ICG/RB-mal under
NIR irradiation, simultaneously achieving selective PTT effects.
Most importantly, tumor-derived antigens released from the
ablated tumor could be captured and retained in situ due to
the functionality of maleimide. It would further enhance the
tumor antigen uptake and recruitment of antigen-presenting
cells, such as dendritic cells. The synergized photothermal,
photodynamic, and immunological effects from NIR-activated
UCNP/ICG/RB-mal induced tumor-specific immune responses
and eliminated the primary distant tumors in using a 4T1-tumor
mouse model (Wang et al., 2019).
A cascade bioreactor for synergistic cancer therapy
combining chemo-dynamic therapy (CDT)/starvation
therapy/phototherapy/immunotherapy was developed based on
hollow structured Cu2MoS4 nanoparticles loaded with glucose
oxidase (GOx) (Chang et al., 2019). The hollow Cu2MoS4 was
well capable of chemical dynamic therapy from the generation
of the hydroxyl radicals (OH) through the chemical reactions of
the redox couples of Cu1+/2+ and Mo4+/6+. The radicals also
could deplete the overexpressed glutathione to modify the tumor
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FIGURE 9 | The schematic illustration of the synergistic photo/immunotherapy using OSPS nanoplatform. (A) Illustration of photoactivation of OSPS for synergistic
therapeutic action including phototherapy and checkpoint blockade immunotherapy. (B) Structure and NIR photo activation mechanism of OSPS (Li et al., 2019,
#45). Reproduced with permission from reference Li et al. (2019).
microenvironment aiming for the mitigation of antioxidant
capability of the tumors.
Furthermore, the Cu2MoS4 could catalyze the reaction
of endogenous H2O2 to O2 which would react with glucose
and produce H2O2 again under the catalysis of GOx. The
consummation of glucose could shut down nutrient supply
to cancer cells and achieve starvation therapy. At the
same time, the phototherapy effect of the Cu2MoS4 under
1064 nm NIR light irradiation was demonstrated by the
strong tumor-killing capacity due to its excellent photothermal
conversion efficiency. More importantly, the PEGylated
Cu2MoS4@GOx-based synergistic therapy combined with
checkpoint blockade therapy could elicite robust immune
responses for both effectively ablating primary tumors and
inhibiting cancer metastasis.
The aforementioned photo/immunotherapy are summarized
in Table 1 including the PDT synergized immunotherapy,
PTT synergized immunotherapy, photochemistry based
therapy synergized immunotherapy and multiple phototherapy
synergized immunotherapy.
PERSPECTIVES AND CONCLUSION
Challenges and promising solutions are ahead of the success
of photo/immunotherapy in cancer treatment. One of the
major challenges is the lack of clinical trial results. Preclinical
research in animals has shown that the photoimmunotherapy
can eliminate tumor cells and enhance tumor-cell-selective
systemic host-immunity leading to boosted antitumor effects



























Targeted Cancer Effectiveness References
PTT Adoptive cell transfer Gold nanoshells 808 nm Metastatic Melanoma − Elimination of metastatic melanoma Bear et al., 2013
Checkpoint blockade PEGylated SWNTs 808 nm Lung metastasis model − Effective rejection of secondary tumors
− Minimized tumor metastasis
Wang et al., 2014
Therapeutic vaccines Optical fiber 980 nm Pancreatic tumor
model
− Complete regression of primary tumor
− Triggered tumor-specific immune memory and production of
memory T cells
Zhou et al., 2018
Checkpoint blockade Gold nanoparticles 1086 nm Breast cancer model − Long-term tumor control over both primary and
secondary tumors
Ma et al., 2019
Polypyrrole nanosheets − Striking therapeutic effects against whole-body
tumor metastasis
Therapeutic vaccines Chitosan-coated hollow
CuS nanoparticles
900 nm Breast cancer model − Combined anticancer effects against primary treated as well as
distant untreated tumors
Guo et al., 2014
Checkpoint blockade Polydopamine-carbon
dots
808 nm Breast cancer model − Ablation of the primary tumor
− Amplified stronger infiltration of CTLs into distant tumors
Lu et al., 2019
Checkpoint blockade SWCNTs 1064 nm 4T1 murine breast
cancer model
− Effectively suppression on primary tumors
− Inhabitation of metastatic cancers
Li et al., 2019a
PDT - Au nanocages @MnO2 808 nm Metastatic
triple-negative breast
cancer
− In situ oxygenation to ameliorate the hypoxia environment in
tumor area
− High PDT efficacy and elicited antitumor immune response
− Elimination of primary tumor and inhabited lung metastasis
Liang et al., 2018
Checkpoint blockade UCNPs +
Chlorin e6
980 nm Mouse colon
adenocarcinoma
(CT26)
− Enhanced tissue penetration depth thus effective photodynamic
destruction of tumors
− The generated a pool of tumor-associated antigens, together
with CTLA4 resulted in strong antitumor immunities to inhibit the
growth of distant tumors
− A long-term immune memory function to protect treated mice
from tumor cell rechallenge
Xu et al., 2017
vaccine UCNPs@large pore
silica + merocyanine
540 + OVA/TF agent
980 nm Mouse colon
adenocarcinoma
− Largely load photosensitizer and immune antigens
− Great cellular uptake
− Enhanced immunotherapy efficacy and new approach to
advanced vaccine delivery system for cancer therapy

















































Targeted Cancer Effectiveness References
PCT Monoclonal antibodies Silica-phthalocyanine
dye (IR700)
690 nm B-cell lymphoma,
prostate cancer,
hepatocellular cancer
− Photosensitizer molecule was conjugated to monoclonal
antibodies
− Photochemistry therapy destructed the primary tumor within
1 min under NIR irradiation
Hanaoka et al., 2015;
Nagaya et al., 2016a,b,
2017; Ogawa et al.,




690 nm Colon and lung cancer − Elimination of primary tumor
− Durable antitumor immunity eradicated both treated and distant
untreated tumors
Nagaya et al., 2019
Cytokine UCNPs/CpG 980 nm Mouse 4T1 breast
cancer
− Immunotherapeutic agents delivered into cancer cells and
released upon the remote NIR light irradiation.
Chu et al., 2019







− With the small size (26 nm) and stealthy PEG surface, OSPS
could effectively accumulate into the tumors of living mice after
systemic administration.
− Upon the 808 nm light irradiation, PTT and PDT ablated the
primary tumor.
−
1O2 also cleaved the conjugated immunostimulant and inhibited
the growth of both primary and distant tumors and suppressed
lung metastasis.
− Low in vivo toxicity.
Li et al., 2019










− Negligible toxicity to normal tissues
− Remarkable damage to tumors in vivo
Chen et al., 2019
PTT + PDT Checkpoint blockade Polydopamine +
UCNPs + Ce6
980 nm Mouse 4T1 breast
cancer
− Significant eradication of the primary tumors from PDT and PTT.
− Effective delay to untreated distal tumor from the combined
checkpoint blockade therapy.
Yan et al., 2019










− Great biosafety of the combined treatment approach.
− Effective primary tumor ablation from PTT, CDT and starvation
therapy;
− Inhabitation of distant tumor and lung metastasis.
Chang et al., 2019
PTT + PDT Checkpoint blockade UCNPs + ICG + RB +
DSPE-PEG-maleimide
805 nm Mouse 4T1 breast
cancer
− Efficient destruction of primary tumor;
− Inhabitation of metastasis by simultaneously boosting specific
immune response and checkpoint blockade.
− Strong long-term antitumor immune memory function.
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triggered by NIR light. However, due to the species difference
and complexity of human in vivo microenvironment, the
performance of photoimmunotherapy in human is barely
predicted. For example, Sato et al. (2014) compared the
performance of two types of photoimmunotherapy agents,
cetuximab-IR700 and panitumumab-IR700, in EGFR positive
mouse tumor models. Although panitumumab-IR700 showed
better antitumor efficiency than cetuximab-IR700 in the mice
models, it is not possible to conclude their performance in human
bodies (Sato et al., 2014). Luckily, a NIR-PIT using cetuximab-
IR700 (RM1929) targeting EGFR in inoperable recurrent head
and neck cancer is in a phase III trial, which is currently
underway in several countries in Asia, North America, and
Europe (Kobayashi and Choyke, 2019). It is expected that
more photoimmunotherapy agents will be tested in clinical
trials and the results will bring more valuable information for
immunotherapy research. In addition to the clinical trials, the
recent progress in organoids and organ-on-chips research may
also provide tools for the exploitation of photoimmunotherapy
(Yin et al., 2016; Brassard and Lutolf, 2019).
Functional targeting moieties and targeting efficiency is
another critical factor that would influence the localized
treatment. The targeting moieties bind surface markers on
the cancer cells, dominating the specificity and distribution of
the photoimmunotherapy agents. Various targeting moieties
including antibodies, peptides, functional molecules and
oligonucleotides have been conjugated with the photoactivation
complexes (Kobayashi and Choyke, 2019; Shirasu et al., 2019).
More specific targeting moieties will be the key to improve the
efficiency of eliminating cancer cells while to reduce the side
effects to the healthy cells. Targeting moieties for circulating
and metastatic cancer cells are also highly desired in order to
promote the prognosis after photoimmunotherapy treatment.
The recent advances have applied multiple targeting groups in
the photoimmunotherapy agents, aiming for cancer cells and
immunocytes, respectively. The stroma cells, such as cancer-
associated fibroblasts, may also be considered as a target in the
photoimmunotherapy treatment (Shirasu et al., 2019).
The nanomaterials provide a large pool of candidates
as the photoactivated cores for photoimmunotherapy. The
development of nanomaterials with low cytotoxicity, high
photoactivity, and multifunctionality will facilitate the clinical
application of cancer photoimmunotherapy. Proper NIR light
is required for deep penetration into the tumour tissues,
dependent on the nanomaterials applied in the therapy. The
energy of NIR light dramatically decreases with the depth of the
tissue, for example, NIR photoimmunotherapy through bone is
limited to 3 mm when using 810 nm NIR of less than 1 W
(Nakamura et al., 2019). Improving the energy transfer efficiency
of nanomaterials is critical for the treatment of cancers in the
deep body with NIR in the biosafety range. An example is
polydopamine coating improved the absorption capacity of gold
nanoparticles, reported by Nam et al. (2019). It has been reported
that IR700-formed APC showed a biodistribution similar to
non-conjugated parental antibodies, once injected intravenously,
the APC will have a sufficient accumulation in the tumors
(Mitsunaga et al., 2011; Nagaya et al., 2018). However, it is
still challenging for the nanomaterials-based phototherapy that
the recognization and clearance of the nanomaterials by the
cells in liver, spleen and other parts of the reticuloendothelial
system (RES) may reduce the concentration of the therapeutics
in the tumor sites. The intratumoral route of administration are
generally chosen to overcome the RES uptake and low time blood
circulation. In addition, nanomateriasl are often modified with
PEG (PEGylation) (Gao et al., 2020) or zwitterionic polymers
(Zheng et al., 2019) to hide the nanomaterials from the RES cells
and to enhance the accumulation at tumors.
Well-integrated photo/immunotherapeutic modalities will
benefit the single administration and working simultaneously.
PTT and PDT, in combination with immunotherapies, provide
infinite possibilities as a promising method to treat cancer. The
administration or conjugation of antibodies or gene silencing
agents aiming to immune checkpoint pathways with PTT and
PDT open new windows for immunotherapy (Wang W. et al.,
2016). However, the performance and efficiency of integrated
strategies are not always comparable in terms of eradication of
primary tumors, inconsistent results between different models,
and difficulty in conjugating biomarkers. More comprehensive
studies with integrated therapies will benefit the development of
successful photoimmunotherapy agents.
The ultimate goal of the nanomaterials-based phototherapies
is to eradicate cancers completely, including primary
solid tumors and metastatic cancers. With minimized side
effect and maximized treatment efficacy, phototherapy
and immunotherapy are the two most promising
therapeutic modalities and their synergistic combination of
photoimmunotherapy has shown substantial potentials to realize
the ultimate goal.
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